



NDA 21085/S-061 & S-062
NDA 21277/S-057 & S-058

SUPPLEMENT APPROVAL

Bayer HealthCare Pharmaceuticals Inc.
Attention: Kristie T. Ota, Ph.D.
Regional Regulatory Manager, Global Regulatory Affairs
P.O. Box 0915
100 Bayer Boulevard
Whippany, NJ 07981-0915

Dear Dr. Ota:

Please refer to your Supplemental New Drug Applications (sNDAs) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

Name of Product/NDA Number	Supplement Number	Submission Date
Avelox (moxifloxacin hydrochloride) Tablets/NDA 21-085	S-061 S-062	September 11, 2015 September 25, 2015
Avelox I.V. (moxifloxacin hydrochloride in sodium chloride injection)/NDA 21-277	S-057 S-058	September 11, 2015 September 25, 2015

Supplement Numbers S-061 and S-057:

Prior Approval supplemental new drug applications S-061 and S-057 provide for revisions to the U.S. Prescribing Information (PI) as follows:

- **Section 3, DOSAGE FORMS AND STRENGTHS**, subsection **3.2 AVELOX Injection** was updated to include “Discard the unused portion of the drug.”
- **Section 8, USE IN SPECIFIC POPULATIONS**, subsection **8.1 Pregnancy** and subsection **8.2 Lactation** were revised to be compliant with the Pregnancy and Lactation Labeling Final Rule (PLLR). In addition, subsection **8.4 Pediatric Use** was revised to include the results of a trial to evaluate the safety of moxifloxacin in pediatric patients with complicated intra-abdominal infections.
- **Section 16, HOW SUPPLIED STORAGE AND HANDLING** was revised to add “moxifloxacin hydrochloride equivalent to 400 mg moxifloxacin” and include “Discard unused portion.”

In addition, these supplements include the replacement of the term “single-use” with “single-dose” throughout the PI, and other minor editorial revisions.

The Carton and Container, the Flexibag and the Overwrap labels were revised to update the presentation order of the established name, strength, and the equivalency statement and to make them consistent with the PI.

Supplement Numbers S-062 and S-058:

Prior Approval supplemental new drug applications S-062 and S-058 provide for revisions to **Section 12, CLINICAL PHARMACOLOGY**, subsection **12.4 MICROBIOLOGY**, to update the susceptibility test interpretive criteria and quality control range for *Staphylococcus aureus*, and to **Section 15 REFERENCES**.

Additionally, these supplements provide for the addition of “Do not administer AVELOX if particulate matter and/or discoloration is observed” to **Section 2 DOSAGE AND ADMINISTRATION**, subsection **2.2 Important Administration Instructions**.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

We acknowledge your September 08, 2016, submission containing final printed carton and container labels.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We note that you have fulfilled the pediatric study requirement (PMR 2898-2) listed in our approval letter dated May 08, 2015.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For

more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Fariba Izadi, Pharm.D., Regulatory Health Project Manager, at (301) 796-0563.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):

Content of Labeling

Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
09/27/2016